journal article·2024-08Open access

Protein Aggregation on Metal Oxides Governs Catalytic Activity and Cellular Uptake

Robert Nißler, Lena Dennebouy, Alexander Gogos, Lukas R.H. Gerken, Maximilian Dommke, Monika Zimmermann, Michael A. Pais, Anna L. Neuer, Martin T. Matter, Vera M. Kissling, Simone de Brot, Ioana Lese, Inge K. Herrmann

Small· Volume 20· Issue 34

Abstract

Abstract Engineering of catalytically active inorganic nanomaterials holds promising prospects for biomedicine. Catalytically active metal oxides show applications in enhancing wound healing but have also been employed to induce cell death in photodynamic or radiation therapy. Upon introduction into a biological system, nanomaterials are exposed to complex fluids, causing interaction and adsorption of ions and proteins. While protein corona formation on nanomaterials is acknowledged, its modulation of nanomaterial catalytic efficacy is less understood. In this study, proteomic analyses and nano‐analytic methodologies quantify and characterize adsorbed proteins, correlating this protein layer with metal oxide catalytic activity in vitro and in vivo. The protein corona comprises up to 280 different proteins, constituting up to 38% by weight. Enhanced complement factors and other opsonins on nanocatalyst surfaces lead to their uptake into macrophages when applied topically, localizing >99% of the nanomaterials in tissue‐resident macrophages. Initially, the formation of the protein corona significantly reduces the nanocatalysts' activity, but this activity can be partially recovered in endosomal conditions due to the proteolytic degradation of the corona. Overall, the research reveals the complex relationship between physisorbed proteins and the catalytic characteristics of specific metal oxide nanoparticles, providing design parameters for optimizing nanocatalysts in complex biological environments.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanoparticle Systems Engineering Laboratory, Institute of Energy and Process Engineering (IEPE), Department of Mechanical and Process Engineering (D‐MAVT) ETH Zurich Sonneggstrasse 3 Zurich 8092 Switzerland

Particles‐Biology Interactions, Department of Materials Meet Life Swiss Federal Laboratories for Materials Science and Technology (Empa) Lerchenfeldstrasse 5 St. Gallen 9014 Switzerland

The Ingenuity Lab, University Hospital Balgrist University of Zurich Forchstrasse 340 Zurich 8008 Switzerland

Institute of Technical Chemistry and Environmental Chemistry Friedrich Schiller University Jena Philosophenweg 7a 07743 Jena Germany

Department of Plastic and Hand Surgery, Inselspital Bern University Hospital Bern 3010 Switzerland

COMPATH, Institute of Animal Pathology University of Bern Bern 3012 Switzerland

Funding

Swiss Cancer Research Foundation · Eidgenössische Technische Hochschule Zürich · Innosuisse - Schweizerische Agentur für Innovationsförderung · ETH Zürich Foundation · Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

References (71)

Show source-provided references
1. 10.1016/j.tibtech.2017.09.00610.1016/j.tibtech.2017.09.006 ↗
2. 10.1016/j.procbio.2023.06.01410.1016/j.procbio.2023.06.014 ↗
3. 10.1002/btm2.1014310.1002/btm2.10143 ↗
4. 10.1021/acsnano.6b0604010.1021/acsnano.6b06040 ↗
5. 10.1002/advs.20200091210.1002/advs.202000912 ↗
6. 10.1371/journal.pone.020780210.1371/journal.pone.0207802 ↗
7. 10.1021/acsami.5b0985310.1021/acsami.5b09853 ↗
8. 10.3390/jdb302005710.3390/jdb3020057 ↗
9. 10.1038/s41467-022-29772-w10.1038/s41467-022-29772-w ↗
10. Ma X. · ACS Appl. Mater. Interfaces · 2022 · 15
11. Cai X. · Mol. Vision · 2016 · 22 · 1176
12. 10.1016/j.actbio.2012.01.03510.1016/j.actbio.2012.01.035 ↗
13. 10.1016/j.snb.2018.10.04010.1016/j.snb.2018.10.040 ↗
14. 10.1038/srep3534410.1038/srep35344 ↗
15. 10.1038/s41427-021-00303-110.1038/s41427-021-00303-1 ↗
16. Kwatra D. · Transl Cancer Res · 2013 · 2 · 330
17. 10.1038/s41467-022-30982-510.1038/s41467-022-30982-5 ↗
18. 10.1021/acs.chemmater.0c0456510.1021/acs.chemmater.0c04565 ↗
19. 10.1039/D3BM00607G10.1039/D3BM00607G ↗
20. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
21. 10.1039/C4EN00079J10.1039/C4EN00079J ↗
22. 10.1021/jp500791j10.1021/jp500791j ↗
23. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗
24. 10.1038/s41578-023-00552-210.1038/s41578-023-00552-2 ↗
25. 10.1038/nnano.2012.20710.1038/nnano.2012.207 ↗
26. 10.1021/nn201950e10.1021/nn201950e ↗
27. 10.1039/D1TB01063H10.1039/D1TB01063H ↗
28. 10.1016/j.rpor.2018.05.00510.1016/j.rpor.2018.05.005 ↗
29. 10.3389/fimmu.2020.56736510.3389/fimmu.2020.567365 ↗
30. 10.3390/ma1212199110.3390/ma12121991 ↗
31. 10.1021/acsnano.0c0062910.1021/acsnano.0c00629 ↗
32. 10.1021/acsami.8b1877810.1021/acsami.8b18778 ↗
33. 10.3390/ma1418544010.3390/ma14185440 ↗
34. 10.3390/app1310615110.3390/app13106151 ↗
35. 10.1021/acsbiomaterials.1c0028310.1021/acsbiomaterials.1c00283 ↗
36. 10.1002/aic.1688510.1002/aic.16885 ↗
37. 10.1039/D2LC00799A10.1039/D2LC00799A ↗
38. 10.3390/ma1314309310.3390/ma13143093 ↗
39. 10.1016/j.biomaterials.2007.07.02910.1016/j.biomaterials.2007.07.029 ↗
40. 10.3390/pharmaceutics1412260510.3390/pharmaceutics14122605 ↗
41. 10.3390/ijms2214762510.3390/ijms22147625 ↗
42. 10.3390/biomimetics703012610.3390/biomimetics7030126 ↗
43. 10.1038/s41596-019-0128-810.1038/s41596-019-0128-8 ↗
44. 10.1101/gr.77240310.1101/gr.772403 ↗
45. 10.1038/s41467-020-20884-910.1038/s41467-020-20884-9 ↗
46. 10.1126/sciadv.abm089810.1126/sciadv.abm0898 ↗
47. 10.1002/advs.20200091210.1002/advs.202000912 ↗
48. 10.1016/j.susc.2004.05.13810.1016/j.susc.2004.05.138 ↗
49. 10.1039/c0nr00875c10.1039/c0nr00875c ↗
50. 10.1039/b922024k10.1039/b922024k ↗
51. 10.1039/C8NR00325D10.1039/C8NR00325D ↗
52. 10.1002/smll.20110151110.1002/smll.201101511 ↗
53. 10.1038/nnano.2015.33010.1038/nnano.2015.330 ↗
54. 10.1039/D1NR02065J10.1039/D1NR02065J ↗
55. 10.3389/fbioe.2022.88236310.3389/fbioe.2022.882363 ↗
56. 10.1021/acsami.0c1234110.1021/acsami.0c12341 ↗
57. 10.1039/D0NA00863J10.1039/D0NA00863J ↗
58. J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal https://pharmaphorum.com/news/jj‐snaps‐nanobiotix‐cancer‐radiotherapy‐25bn‐deal(accessed: March 2024).
59. Nanobiotix. NBTXR3 With or Without Cetuximab in LA‐HNSCC https://clinicaltrials.gov/study/NCT04892173(accessed: March 2024).
60. 10.1021/jacsau.1c0056510.1021/jacsau.1c00565 ↗
61. 10.3389/fmolb.2020.58701210.3389/fmolb.2020.587012 ↗
62. 10.1039/D0NR08285F10.1039/D0NR08285F ↗
63. 10.1586/17434440.2.3.30310.1586/17434440.2.3.303 ↗
64. 10.1039/C7NR01176H10.1039/C7NR01176H ↗
65. 10.1021/acs.chemmater.7b0217010.1021/acs.chemmater.7b02170 ↗
66. 10.1016/j.porgcoat.2017.02.00810.1016/j.porgcoat.2017.02.008 ↗
67. 10.1088/0957-4484/22/14/14510110.1088/0957-4484/22/14/145101 ↗
68. 10.1002/anie.20200817510.1002/anie.202008175 ↗
69. 10.1093/nar/gkab103810.1093/nar/gkab1038 ↗
70. 10.1136/bmjos-2020-10011510.1136/bmjos-2020-100115 ↗
71. 10.1038/nprot.2014.13910.1038/nprot.2014.139 ↗